Helus Pharma Appoints Dr. Suresh Durgam to Board
The pharmaceutical company taps industry veteran Dr. Suresh Durgam to provide strategic oversight and clinical expertise.
Updated on Oct. 15, 2026 in People
Live Poll
Does a company's leadership team impact your trust in the safety of its new medical treatments?
Helus Pharma has appointed Dr. Suresh Durgam to its Board of Directors, a move aimed at bolstering the company's clinical development and regulatory strategy. Dr. Durgam, a recipient of the 2026 International Society for CNS Drug Development Leadership Award, will support corporate governance as the firm advances its pipeline toward commercialisation.
Why it matters
The appointment strengthens Helus Pharma's leadership team with significant expertise in central nervous system drug development. This addition is intended to help the company navigate complex clinical and regulatory milestones as it pushes forward with its commercial goals.
Dr. Durgam has authored 50 peer-reviewed publications and over 200 abstracts and posters throughout his career. His appointment is currently subject to formal approval by Cboe Canada.
The players
Dr. Suresh Durgam
He is an experienced medical executive who previously served as the Chief Medical Officer at Intra-Cellular Therapies, Inc. and received the 2026 International Society for CNS Drug Development Leadership Award.
Helus Pharma
It is a pharmaceutical company that maintains corporate offices in Toronto and New York and is focused on advancing its drug pipeline toward commercialisation.
Cboe Canada
It is an exchange operator that oversees regulatory compliance and listing requirements for publicly traded companies in the Canadian market.
The details
Dr. Durgam joins the board following a tenure on the Helus Pharma Scientific Advisory Board, bringing experience from his previous role as Executive Vice President and Chief Medical Officer at Intra-Cellular Therapies, Inc. His background in regulatory strategy is expected to assist the company as it works to reach key commercial and development targets.
Timeline
April 2025: Intra-Cellular Therapies, Inc. was acquired by Johnson & Johnson.
October 15, 2026: Helus Pharma officially announced the appointment of Dr. Durgam.
Market Landscape
The appointment aligns Helus Pharma with industry standards established by the 2026 International Society for CNS Drug Development Leadership Award. This recruitment reflects a broader trend of mid-sized pharmaceutical firms securing seasoned clinical leadership to navigate high-stakes commercialisation phases.
For shareholders and observers, this appointment signals a push to accelerate the company's clinical pipeline development. No immediate changes to existing drug pricing or consumer-facing products have been announced as a result of this board addition.
The takeaway
Dr. Durgam brings extensive academic and clinical experience to the board, which may help Helus Pharma bridge the gap between early-stage research and market entry. Investors should monitor future clinical trial updates as the board begins its new oversight role.
Further reading
For more information on executive moves in the pharmaceutical sector, visit the Canada People section.
Live Poll
Does a company's leadership team impact your trust in the safety of its new medical treatments?
